Oral Semaglutide (Wegovy® Pill): 7mg

Regulatory Notice (June 2026): Oral semaglutide (Wegovy® Pill) received FDA approval for weight management in January 2026. It is an approved prescription pharmaceutical — not a research peptide. Only FDA-approved branded Wegovy® Pill is legal for human use. Compounded oral semaglutide is not authorized. This 503B exclusion proposal (April 30, 2026) does not directly change oral semaglutide status, as it targets injectable bulk compounding. FDA Enforcement Action — Misleading Compounded GLP-1 Marketing (March 3, 2026): On March 3, 2026, the FDA issued 30 warning letters to telehealth companies for making false or misleading marketing claims about compounded GLP-1 receptor agonist products, including claims implying equivalence to FDA-approved brand-name medications (Ozempic, Wegovy, Mounjaro, Zepbound) and branding that obscured the identity of the actual compounder. This is a distinct enforcement action — separate from the 503B exclusion proposal (April 30, 2026) — and targets promotional violations rather than compounding authorization. Researchers and clinicians following this space should be aware that FDA is actively enforcing truthful labeling rules in the compounded GLP-1 market. Source: FDA press announcement (fda.gov, March 3, 2026); Reuters (March 3, 2026). Fifth Circuit Court of Appeals — GLP-1 Compounding Ruling (August 27, 2026): On August 27, 2026, the U.S. Court of Appeals for the Fifth Circuit affirmed two lower-court judgments upholding the FDA's removal of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) from the national drug shortage list. Because federal law (21 U.S.C. § 353a/353b) only permits compounding copies of an approved drug while it remains in shortage, this ruling removes the shortage-based legal basis for bulk compounding of these agents. 503A patient-specific compounding for individual patients with documented medical needs remains a separate, narrower pathway. 503B outsourcing facility bulk production of essentially-equivalent copies is no longer supported by a shortage justification. The ruling does not affect the separate FDA rulemaking (503B exclusion proposal, April 30, 2026) which is still under agency review. Sources: teleranked.com (August 27, 2026); peptidesbeat.com (August 27, 2026); courthousenews.com. FDA Import Alert 66-80 — GLP-1 API Detention (August 21, 2026): On August 21, 2026, the FDA published a major revision to Import Alert 66-80, authorising Detention Without Physical Examination (DWPE) of foreign-sourced GLP-1 receptor agonist bulk drug substances — including semaglutide, tirzepatide, liraglutide, exenatide, dulaglutide, and related peptide APIs — at U.S. ports of entry. The alert accompanies the FDA's "green list" program: manufacturers that have passed FDA inspection and cGMP review can apply to be exempted from automatic detention. Facilities that have not responded to FDA inspection requests or have been found non-compliant remain subject to DWPE. Practically, this means bulk GLP-1 API imported from foreign sources without green-list status can be detained and refused entry without individual inspection. This is a supply-chain enforcement tool targeting the import of raw GLP-1 peptide APIs used in compounding; it does not change whether compounding is otherwise permitted. The alert operates in parallel with the ongoing 503B exclusion rulemaking (comment period closed July 30, 2026, final rule pending) and the Fifth Circuit ruling (August 27, 2026) upholding removal of these agents from shortage status. Source: FDA Import Alert 66-80, accessdata.fda.gov (August 21, 2026); FDA press announcement (fda.gov); Frier Levitt (frierlevitt.com); PeptideKnow.com. FDA Warning Letter — Empower Pharmacy (September 18, 2026): On September 18, 2026, the FDA issued a warning letter (MARCS-CMS 738238) to Empower Clinic Services, LLC dba Empower Pharmacy (Houston, TX) — one of the largest 503A compounding pharmacies in the United States. The FDA cited three compounded semaglutide and tirzepatide presentations — including vitamin-blend formulations — as essentially copies of FDA-approved Ozempic, Wegovy, Mounjaro, and Zepbound, stripping them of the 503A exemptions from CGMP requirements, adequate directions for use, and premarket approval. The letter also cited insanitary conditions and violations relating to the scale of production, arguing the volume exceeded what qualifies as patient-specific 503A compounding. This is the third FDA warning letter Empower has received related to GLP-1 compounding. Empower has 15 business days to respond. The letter does not constitute a mandatory recall or facility closure, but escalates FDA's enforcement posture significantly against high-volume 503A compounding of GLP-1 agents. Source: FDA warning letter MARCS-CMS 738238, fda.gov (September 18, 2026); Endpoints News (September 23, 2026); Partnership for Safe Medicines (September 23, 2026).